According to study, “Global Mildronate Dihydrate Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024” the key companies operating in the global mildronate dihydrate market arePsypharm, Jinan Chenghui-shuangda Chemical, Latvian company, Farmasino, Pink Lotus Skin Clinic, Canadian Pharmacy, United Pharmacies, Grindex Company, Shandong Chengchuang, Warehouse, Slovakia, Merz, chemBlink, Casa Tania, TSSC.
Mildronate is a registered attribute of the Grindex. Its active ingredient is meldonium, which is a limited-market pharmaceutical, and an ‘anti-ischemic’ drug. It is used to treat inadequate blood-flow to the organs, specifically the heart. Mildronate dihydrate is a reasonable inhibitor of renal carnitine reabsorption and an inhibitor of biosynthesis of L-carnitineusing gamma-butyrobetaine (GBB) hydroxylase. Its formation has a high technology barrier therefore it is a technology severe industry. It is mainly used to treat patients with heart conditions that affect the body’s ability to provide oxygen to the body. It helps to protect against tissue damage from chronic heart failure, angina attacks, and disorders of brain circulation. It may also help to reduce withdrawal symptoms in people with alcohol dependency. Some other possible uses for meldonium include treating stomach ulcers, immune system modulation, treating infections of the lungs & upper respiratory tract and treating eye trauma.
The key mechanism of mildronate dehydrate is based on carnitine bio-synthesis inhibition proposed to inhibit the growth of cytotoxic intermediate products of fatty acid beta-oxidation in ischemic matters and to block this enormously oxygen-consuming process. Some of the side-effects are included nervousness, sleeplessness, headache, dizziness, allergic symptoms, a fall in blood pressure, and tachycardia.
Based on formtype, mildronate dihydrate market is segmented intomildronate dihydrate tablet, mildronate dihydrate injection and mildronate dihydrate capsule. The mildronate dihydrate capsule segment contains 500mg active ingredient. Based on raw materials, market is segmented into unsymmetrical dimethylhydrazine (UDMH), tert-Butyl acrylate (TBA) and ethanol, etc. In addition, based on application, market is segmented into cardiovascular diseases, narcology (abstinence syndrome in chronic alcoholism), pulmonology, neurology, ophthalmology and others (treating wye trauma & stomach ulcers, immune system modulation, and treating infection of lungs & upper respiratory tract). Cardiovascular diseases include chronic heart failure, treatment of chronic heart ischemic disease, stable angina pectoris, heart infarction, functional disorders of heart & vessels and cardiomyopathy. Pulmonology segment includes obstructive bronchitis and bronchial asthma. Neurology segment includes physical & emotional overload, acute & chronic ischemic brain circulation disorders, recovery period after various diseases and decreased work capabilities. Additionally, ophthalmology segment includes diabetic & hypertonic retinopathies, hemophthalm & retina hemorrhages of different etiology, thrombosis of central vein & its branches in retina. In addition, based on end-use, market is segmented into academic institutes & research institutions, hospitals & clinics and others.
The mildronate dihydrate market is driven by rise in favorable government initiatives related to the use of Mildronate Dihydrate, followed by increase in cardiovascular disease, growth in awareness of the patient population, increase in patient population, and rise in technological advancements. However, lack of funding for research & development (R&D) and price of the upstream product may impact the market. Moreover, rise in disposable income is a key opportunity for market.
Based on geography, the North-American region holds major share, followed by European region in mildronate dihydrate market owing to better infrastructure & technological edge and presence of highly skilled medical professionals in the region. The Asian-Pacific region is expected to witness higher growth rate due to increase in cardiovascular disease, presence of several major vendors and rise in aged population over the forecast period. It is predicted that the market will be reached at rapid pace on account of high growth potential in emerging economies during the forecast period.
For more information on the research report, refer to below link:
Ankur Gupta, Head Marketing & Communications